Genspeed Biotech is developing the first COVID19 point-of-care test, which makes it possible to test both infected and recovered patients in a single run in just a few minutes.
The development of the test is supported by the Austrian Research Promotion Agency FFG within the COVID-19 Emergency Call. In the final stage of development, the combined test allows the simultaneous detection of antibodies as well as an acute virus infection in laboratory quality within a few minutes. This makes the test unique in the world, as it is the first to be able to identify immune or acutely infected persons on site, quickly and reliably. The range of applications is broad: whether for testing patients in medical practices, staff or visitors to health care facilities or companies as well as of travelers at airports.
Cooperations with medical research partners such as the Medical Faculty of the Johannes Kepler University, the Medical University of Graz, the Ludwig Boltzmann Institute and the BOKU in Vienna enable the highest quality in the implementation of the project. In any case, the first COVID-19 measurement results are very promising.
Contact: Kerstin Schanda Corporate Communications +43 664 819 3022 Kerstin.email@example.com